Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|September 16, 2022
Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institutionRaquel Jiménez-Segura, Laura Rosiñol, Ma Teresa Cibeira, et al.
British Journal of Haematology|October 8, 2021
Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year periodLuis Gerardo Rodríguez-Lobato, Arturo Pereira, Carlos Fernández de Larrea, et al.
Cancers|November 14, 2023
Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single InstitutionLuis Gerardo Rodríguez-Lobato, Natalia Tovar, Anna de Daniel, et al.
Hemasphere|May 8, 2024
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myelomaAnna de Daniel, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 24, 2022
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue PlasmacytomasDavid F Moreno, Victoria Clapés, Juan Alfons Soler, et al.
Molecular Therapy. Methods & Clinical Development|July 21, 2022
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cellsAnthony M Battram, Aina Oliver-Caldés, Maria Suárez-Lledó, et al.
Transfusion|May 29, 2019
Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host diseaseJoan Cid, Gloria Carbassé, María Suárez-Lledó, et al.
Frontiers in Immunology|December 9, 2021
Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic DiseaseIgnacio Isola, Fara Brasó-Maristany, David F Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2024
Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple MyelomaEster Lozano, Mari-Pau Mena, Glòria Garrabou, et al.
Annals of Hematology|August 31, 2021
Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced diseaseIgnacio Isola, David F Moreno, Esther Moga, et al.
Pageof 15